Search alternatives:
significant based » significant cause (Expand Search), significant barrier (Expand Search), significant burden (Expand Search)
linear decrease » linear increase (Expand Search)
based decrease » caused decreased (Expand Search), marked decrease (Expand Search), based defense (Expand Search)
significant based » significant cause (Expand Search), significant barrier (Expand Search), significant burden (Expand Search)
linear decrease » linear increase (Expand Search)
based decrease » caused decreased (Expand Search), marked decrease (Expand Search), based defense (Expand Search)
-
61
Summary of post-treatment disease course measures from MDMA-AT publications.
Published 2025Subjects: -
62
-
63
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
Published 2025Subjects: -
64
-
65
-
66
-
67
Summary of post-treatment disease course measures from off-label medications clinical trials.
Published 2025Subjects: -
68
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
Published 2025Subjects: -
69
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
Published 2025Subjects: -
70
Summary of post-treatment disease course measures from clinical trials with psychotherapies.
Published 2025Subjects: -
71
-
72
-
73
Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.
Published 2025Subjects: -
74
-
75
-
76
-
77
Mean persistence (±SE) of GO and GO-GA NPs on <i>Callosobruchus maculatus.</i>
Published 2025Subjects: -
78
-
79
-
80